Primary Tumor Resection in Colorectal Cancer with Unresectable Synchronous Metastases: A Review

World Journal of Gastrointestinal Oncology

Volumn 6, Issue 6, 2014, Pages 156-169

  Mestier, Louis de ^a   Manceau, Gilles ^b   Neuzillet, Cindy ^c   Bachet, Jean Baptiste ^b   Spano, Jean Philippe ^b   Kianmanesh, Reza ^a   Vaillant, Jean Christophe ^b   Bouché, Olivier ^a   Hannoun, Laurent ^b   Karoui, Mehdi ^b  

^a SERVICE DE DERMATOLOGIE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Chemotherapy; Colorectal cancer; Colorectal primary tumor; Colorectal surgery; Liver metastases; Survival

Indexed keywords

EID: 84922885049     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i6.156     Document Type: Article

References (94)

1. 1 Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carrol! CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187.e1-e3 [PMID: 22885331 DOI: 10.1053/j.gastro.2012.08.002]
2. 2 van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, Verhoef C. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 2012; 14: 56-61 [PMID: 21176063 DOI: 10.1111/j.1463-1318.2010.02539.x]
3. 3 Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985-992 [PMID: 19153115 DOI: 10.1093/annonc/mdn735]
4. 4 Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 8: 898-911 [PMID: 17888735 DOI: 10.1016/ S1470-2045(07)70281-4]
5. 5 Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sin- nige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572 [PMID: 19196673 DOI: 10.1056/NEJMoa0808268]
6. 6 Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resec¬tion in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 2008; 23: 559-568 [PMID: 18330581 DOI: 10.1007/s00384-008-0456-6]
7. 7 Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Manage¬ment of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008; 19: 1829-1835 [PMID: 18662955 DOI: 10.1093/annonc/mdn398]
8. 8 Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010; 34: 797-807 [PMID: 20054541 DOI: 10.1007/s00268-009- 0366-y]
9. 9 Anwar S, Peter MB, Dent J, Scott NA. Palliative excisional surgery for primary colorectal cancer in patients with incur¬able metastatic disease. Is there a survival benefit? A system¬atic review. Colorectal Dis 2012; 14: 920-930 [PMID: 21899714 DOI: 10.1111/j.1463-1318.2011.02817.x]
10. 10 Stillwell AP, Ho YH, Veitch C. Systematic review of prog- nostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 2011; 35: 684-692 [PMID: 21181473 DOI: 10.1007/ s00268-010-0891-8]
11. 11 Chan TW, Brown C, Ho CC, Gill S. Primary tumor resec¬tion in patients presenting with metastatic colorectal can¬cer: analysis of a provincial population-based cohort. Am J Clin Oncol 2010; 33: 52-55 [PMID: 19704367 DOI: 10.1097/ COC.0b013e31819e902d]
12. 12 Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Mol L, Punt CJ, Koopman M. Prognostic value of resection of pri¬mary tumor in patients with stage IV colorectal cancer: ret¬rospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 2011; 18: 3252-3260 [PMID: 21822557 DOI: 10.1245/s10434-011-1951-5]
13. 13 V erhoef C, de Wilt JH, Burger JW, Verheul HM, Koopman M. Surgery of the primary in stage IV colorectal cancer with un- resectable metastases. Eur J Cancer 2011; 47 Suppl 3: S61-S66 [PMID: 21944031 DOI: 10.1016/S0959-8049(11)70148-4]
14. 14 Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal can¬cer. J Clin Oncol 2004; 22: 3475-3484 [PMID: 15337795 DOI: 10.1200/JCO.2004.10.218]
15. 15 Cook AD, Single R, McCahill LE. Surgical resection of pri¬mary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005; 12: 637-645 [PMID: 15965730 DOI: 10.1245/ASO.2005.06.012]
16. 16 Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hain- sworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorec-tal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529 [PMID: 18640933 DOI: 10.1200/JCO.2007.15.4138]
17. 17 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Hol¬mgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovo- rin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
18. 18 Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and effica¬cy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847 [PMID: 19406901 DOI: 10.1093/annonc/mdp233]
19. 19 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as ini¬tial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJ- Moa0805019]
20. 20 Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/ JCO.2008.20.8397]
21. 21 Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, Cherqui D, Tran Van Nhieu J. Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 2008; 15: 3440-3446 [PMID: 18850249 DOI: 10.1245/s10434-008-0167-9]
22. 22 Ferrand F, Malka D, Bourredjem A, Allonier C, Bouche O, Louafi S, Boige V, Mousseau M, Raoul JL, Bedenne L, Leduc B, Deguiral P, Faron M, Pignon JP, Ducreux M. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised tri¬al Federation Francophone de Cancerologie Digestive 9601. Eur J Cancer 2013; 49: 90-97 [PMID: 22926014 DOI: 10.1016/ j.ejca.2012.07.006]
23. 23 Hida K, Hasegawa S, Kinjo Y, Yoshimura K, Inomata M, Ito M, Fukunaga Y, Kanazawa A, Idani H, Sakai Y, Watanabe M. Open versus laparoscopic resection of primary tumor for incurable stage IV colorectal cancer: a large multicenter con¬secutive patients cohort study. Ann Surg 2012; 255: 929-934 [DOI: 10.1097/SLA.0b013e31824a99e4]
24. 24 Akagi T, Inomata M, Kitano S, Hida K, Sakai Y, Hasegawa S, Kinjo Y, Yoshimura K, Ito M, Fukunaga Y, Kanazawa A, Idani H, Watanabe M. Multicenter study of short- and long-term outcomes of laparoscopic palliative resection for incurable, symptomatic stage IV colorectal cancer in Japan. J Gastrointest Surg 2013; 17: 776-783 [PMID: 23435696 DOI: 10.1007/s11605-013-2173-x]
25. 25 Yang TX, Billah B, Morris DL, Chua TC. Palliative resection of the primary tumour in patients with Stage IV colorectal cancer: systematic review and meta-analysis of the early outcome after laparoscopic and open colectomy. Colorectal Dis 2013; 15: e407-e419 [PMID: 23895669 DOI: 10.1111/ codi.12256]
26. 26 Adam R, de Haas RJ, Wicherts DA, Vibert E, Salloum C, Azoulay D, Castaing D. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg 2011; 253: 349-359 [PMID: 21178761 DOI: 10.1097/SLA.0b013e318207bf2c]
27. 27 Maggiori L, Elias D. Curative treatment of colorectal perito¬neal carcinomatosis: current status and future trends. Eur J Surg Oncol 2010; 36: 599-603 [PMID: 20605396 DOI: 10.1016/ j.ejso.2010.05.007]
28. 28 Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulias V, Mavroudis D, Souglakos J. Front-line be- vacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorec¬tal cancer: a multicenter phase II study. BMC Cancer 2007; 7: 91 [PMID: 17537235 DOI: 10.1186/1471-2407-7-91]
29. 29 Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Gui- mbaud R, Delpero JR, Rivoire M, Quenet F, Portier G, Nordlinger B. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metas- tases. Cancer Chemother Pharmacol 2008; 62: 195-201 [PMID: 17901955 DOI: 10.1007/s00280-007-0588-3]
30. 30 Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004; 84: 659-671 [PMID: 15062667 DOI: 10.1016/j.suc.2003.12.005]
31. 31 Stillwell AP, Buettner PG, Siu SK, Stitz RW, Stevenson AR, Ho YH. Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. Dis Colon Rectum 2011; 54: 535-544 [PMID: 21471753 DOI: 10.1007/DCR.0b013e3182083d9d]
32. 32 Chang GJ. Primary tumor resection in stage IV colorectal can¬cer: the debate continues. Dis Colon Rectum 2011; 54: 919-920 [PMID: 21730777 DOI: 10.1097/DCR.0b013e31821ccf05]
33. 33 Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, Louvet C, Landi B, Tiret E, Sobhani I. Primary colectomy in patients with stage IV colon cancer and unre- sectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum 2011; 54: 930-938 [PMID: 21730780 DOI: 10.1097/DCR.0b013e31821cced0]
34. 34 Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingston S, Andreyev J. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52: 568-573 [PMID: 12631671]
35. 35 Law WL, Chan WF, Lee YM, Chu KW. Non-curative sur¬gery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis 2004; 19: 197-202 [PMID: 14618348 DOI: 10.1007/s00384-003-0551-7]
36. 36 Konyalian VR, Rosing DK, Haukoos JS, Dixon MR, Sinow R, Bhaheetharan S, Stamos MJ, Kumar RR. The role of pri¬mary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 2007; 9: 430-437 [PMID: 17504340 DOI: 10.1111/j.1463-1318.2007.01161.x]
37. 37 Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assess¬ment of proper treatment according to the patient's status. Int J Colorectal Dis 2007; 22: 1301-1310 [PMID: 17486358 DOI: 10.1007/s00384-007-0315-x]
38. 38 Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, Zamboli A. First-line chemotherapy vs bowel tu¬mor resection plus chemotherapy for patients with unresect- able synchronous colorectal hepatic metastases. Arch Surg 2008; 143: 352-358; discussion 358 [PMID: 18427022 DOI: 10.1001/archsurg.143.4.352]
39. 39 Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hoch- hauser D, Ledermann JA, O'Bichere A. Primary tumour resection and survival in the palliative management of meta¬static colorectal cancer. Eur J Surg Oncol 2009; 35: 164-167 [PMID: 18644695 DOI: 10.1016/j.ejso.2008.06.005]
40. 40 Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut A, Dziki A. Resection of the primary tumour or other palliative pro¬cedures in incurable stage IV colorectal cancer patients? Colorectal Dis 2010; 12: e61-e67 [PMID: 19486103 DOI: 10.1111/j.1463-1318.2009.01860.x]
41. 41 Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years ex¬perience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg 2010; 8: 305-313 [PMID: 20380899 DOI: 10.1016/j.ijsu.2010.03.005]
42. 42 Yamamura T, Tsukikawa S, Akaishi O, Tanaka K, Matsuoka H, Hanai A, Oikawa H, Ozasa T, Kikuchi K, Matsuzaki H, Yamaguchi S. Multivariate analysis of the prognostic factors of patients with unresectable synchronous liver metastases from colorectal cancer. Dis Colon Rectum 1997; 40: 1425-1429 [PMID: 9407979]
43. 43 Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Mi- chelassi F, Millis JM, Posner MC. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000; 135: 530-534; discussion 534-535 [PMID: 10807276]
44. 44 Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196: 722-728 [PMID: 12742204 DOI: 10.1016/S1072-7515(03)00136-4]
45. 45 Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predict¬ing survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89: 211-217 [PMID: 15726622 DOI: 10.1002/jso.20196]
46. 46 Kleespies A, Fuessl KE, Seeliger H, Eichhorn ME, Muller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW. Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis 2009; 24: 1097-1109 [PMID: 19495779 DOI: 10.1007/ s00384-009-0734-y]
47. 47 Vibert E, Bretagnol F, Alves A, Pocard M, Valleur P, Panis Y. Multivariate analysis of predictive factors for early postoper¬ative death after colorectal surgery in patients with colorec¬tal cancer and synchronous unresectable liver metastases. Dis Colon Rectum 2007; 50: 1776-1782 [PMID: 17710496 DOI: 10.1007/s10350-007-9025-2]
48. 48 Costi R, Di Mauro D, Veronesi L, Ardizzoni A, Salcuni P, Roncoroni L, Sarli L, Violi V. Elective palliative resection of incurable stage IV colorectal cancer: who really benefits from it? Surg Today 2011; 41: 222-229 [PMID: 21264758 DOI: 10.1007/s00595-009-4253-9]
49. 49 Kuo LJ, Leu SY, Liu MC, Jian JJ, Hongiun Cheng S, Chen CM. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum 2003; 46: 1646-1652 [PMID: 14668590 DOI: 10.1097/01.DCR.0000093624.29029.3A]
50. 50 Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED. Ne¬phrectomy followed by interferon alfa-2b compared with in¬terferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659 [PMID: 11759643 DOI: 10.1056/ NEJMoa003013]
51. 51 van der Burg ME, Vergote I. The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep 2003; 5: 473-481 [PMID: 14521806]
52. 52 Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004; 64: 2205-2211 [PMID: 15026364]
53. 53 Holmgren L, O'Reilly MS, Folkman J. Dormancy of micro- metastases: balanced proliferation and apoptosis in the pres¬ence of angiogenesis suppression. Nat Med 1995; 1: 149-153 [PMID: 7585012]
54. 54 Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827 [PMID: 16341007 DOI: 10.1038/nature04186]
55. 55 van der Wal GE, Gouw AS, Kamps JA, Moorlag HE, Bulthuis ML, Molema G, de Jong KP. Angiogenesis in syn¬chronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg 2012; 255: 86-94 [PMID: 22156924 DOI: 10.1097/SLA.0b013e318238346a]
56. 56 Peeters CF, de Waal RM, Wobbes T, Ruers TJ. Metastatic dormancy imposed by the primary tumor: does it exist in humans? Ann Surg Oncol 2008; 15: 3308-3315 [PMID: 18685897 DOI: 10.1245/s10434-008-0029-5]
57. 57 Peeters CF, de Waal RM, Wobbes T, Westphal JR, Ruers TJ. Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer 2006; 119: 1249-1253 [PMID: 16642475 DOI: 10.1002/ijc.21928]
58. 58 Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ. Vascular density in colorectal liver metastases in¬creases after removal of the primary tumor in human cancer patients. Int J Cancer 2004; 112: 554-559 [PMID: 15382035]
59. 59 Scheer MG, Stollman TH, Vogel WV, Boerman OC, Oyen WJ, Ruers TJ. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med 2008; 49: 887-891 [PMID: 18483084 DOI: 10.2967/ jnumed.107.048371]
60. 60 Naumov GN, Folkman J, Straume O, Akslen LA. Tumor-vascu¬lar interactions and tumor dormancy. APMIS 2008; 116: 569-585 [PMID: 18834403 DOI: 10.1111/j.1600-0463.2008.01213.x]
61. 61 Elias D. Impact of tumor doubling time on the therapeutic strategy: application to so-called synchronous metastases of colorectal cancers. Ann Chir 1998; 52: 413-420 [PMID: 9752479]
62. 62 Elias D, Farace F, Triebel F, Hattchouel JM, Pignon JP, Lecesne A, Rougier P, Lasser P, Duvillard P, Escudier B. Phase I-II randomized study on prehepatectomy recombi¬nant interleukin-2 immunotherapy in patients with metastat¬ic carcinoma of the colon and rectum. J Am Coll Surg 1995; 181: 303-310 [PMID: 7551323]
63. 63 Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A, Caprotti R, Uggeri F. Immunodeficiency in different his- totypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res 2004; 23: 195-200 [PMID: 15354402]
64. 64 Weese JL, Gilbertson EM, Syrjala SE, Starling JR. Prevention of rat colon cancer metastases by perioperative immunos- timulation. Surgery 1984; 96: 420-426 [PMID: 6463870]
65. 65 Weese JL, Gilbertson EM, Syrjala SE, Whitney PD, Starling JR. Reduced incidence of rat colon cancer metastases by perioperative immunostimulation with maleic anhydride- divinyl ether-2 (MVE-2). Dis Colon Rectum 1985; 28: 217-221 [PMID: 3979221]
66. 66 Corman J, Arnoux R, Peloquin A, St-Louis G, Smeesters C, Giroux L. Blood transfusions and survival after colectomy for colorectal cancer. Can J Surg 1986; 29: 325-329 [PMID: 3756652]
67. 67 Arnoux R, Corman J, Peloquin A, Smeesters C, St-Louis G. Adverse effect of blood transfusions on patient survival after resection of rectal cancer. Can J Surg 1988; 31: 121-126 [PMID: 3349375]
68. 68 Longo WE, Virgo KS, Johnson FE, Oprian CA, Vernava AM, Wade TP, Phelan MA, Henderson WG, Daley J, Khuri SF. Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum 2000; 43: 83-91 [PMID: 10813129]
69. 69 Legendre H, Vanhuyse F, Caroli-Bosc FX, Pector JC. Survival and quality of life after palliative surgery for neoplastic gas¬trointestinal obstruction. Eur J Surg Oncol 2001; 27: 364-367 [PMID: 11417981 DOI: 10.1053/ejso.2001.1120]
70. 70 Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal can¬cer. World J Surg Oncol 2009; 7: 28 [PMID: 19284542 DOI: 10.1186/1477-7819-7-28]
71. 71 Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O' Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001; 88: 1352-1356 [PMID: 11578291 DOI: 10.1046/ j.0007-1323.2001.01915.x]
72. 72 Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery- Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI fol¬lowed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237 [PMID: 14657227 DOI: 10.1200/ JCO.2004.05.113]
73. 73 Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramana- than RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovo- rin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30 [PMID: 14665611 DOI: 10.1200/ JCO.2004.09.046]
74. 74 Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardi- ello F. Cetuximab plus irinotecan, fluorouracil, and leucovo- rin as first-line treatment for metastatic colorectal cancer: up¬dated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]
75. 75 Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007; 14: 766-770 [PMID: 17103261 DOI: 10.1245/ s10434-006-9146-1]
76. 76 Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Out¬come of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27: 3379-3384 [PMID: 19487380 DOI: 10.1200/JCO.2008.20.9817]
77. 77 McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wag- man LD, O'Connell MJ, Wolmark N. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable meta¬static colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30: 3223-3228 [PMID: 22869888 DOI: 10.1200/JCO.2012.42.4044]
78. 78 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch- Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Peri¬operative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised con¬trolled trial. Lancet 2008; 371: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]
79. 79 Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 2005; 92: 1155-1160 [PMID: 16035135 DOI: 10.1002/bjs.5060]
80. 80 Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitch¬ell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovo- rin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544 [PMID: 17442997 DOI: 10.1200/JCO.2006.09.6305]
81. 81 Zalinski S, Mariette C, Farges O. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version. J Visc Surg 2011; 148: e171-e182 [PMID: 21703959 DOI: 10.1016/j.jviscsurg.2011.05.015]
82. 82 Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6: 651-657 [PMID: 10560850]
83. 83 Platell C, Ng S, O'bichere A, Tebbutt N. Changing manage¬ment and survival in patients with stage IV colorectal cancer. Dis Colon Rectum 2011; 54: 214-219 [PMID: 21228671 DOI: 10.1007/DCR.0b013e3182023bb0]
84. 84 Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J. Long¬term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled tri¬als. Cancer Treat Rev 2008; 34: 498-504 [PMID: 18468803 DOI: 10.1016/j.ctrv.2008.03.011]
85. 85 Chambrier C, Sztark F, the working group of the Societe Francophone de Nutrition Clinique et Metabolisme (SF- NEP) and the Societe Frangaise d'Anesthesie et Reanimation (SFAR). French clinical guidelines on perioperative nutrition. Update of the 1994 consensus conference on perioperative artificial nutrition after elective surgery in adults. Available from: URL: http://www.sfar.org/_docs/articles/ Recom- mandationsNutritionPeriop090111SFAR.pdf
86. 86 Ohtani H, Tamamori Y, Arimoto Y, Nishiguchi Y, Maeda K, Hirakawa K. A meta-analysis of the short- and long¬term results of randomized controlled trials that compared laparoscopy-assisted and open colectomy for colon cancer. J Cancer 2012; 3: 49-57 [PMID: 22315650 DOI: 10.7150/jca.3621]
87. 87 den Dulk M, Smit M, Peeters KC, Kranenbarg EM, Rutten HJ, Wiggers T, Putter H, van de Velde CJ. A multivariate analysis of limiting factors for stoma reversal in patients with rectal cancer entered into the total mesorectal excision (TME) trial: a retrospective study. Lancet Oncol 2007; 8: 297-303 [PMID: 17395102 DOI: 10.1016/S1470-2045(07)70047-5]
88. 88 Stelzner S, Hellmich G, Jackisch T, Ludwig K, Witzigmann H. Selective surgical treatment of patients with rectal carci-noma and unresectable synchronous metastases based on response to preoperative chemotherapy. J Gastrointest Surg 2008; 12: 1246-1250 [PMID: 18340498 DOI: 10.1007/s11605-008-0506-y]
89. 89 Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI- defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-248 [PMID: 20106720 DOI: 10.1016/S1470- 2045(09)70381-X]
90. 90 Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, Paillot B. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroen¬terol Clin Biol 2004; 28: 434-437 [PMID: 15243315]
91. 91 Costi R, Mazzeo A, Di Mauro D, Veronesi L, Sansebastiano G, Violi V, Roncoroni L, Sarli L. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol 2007; 14: 2567-2576 [PMID: 17541693 DOI: 10.1245/s10434-007-9444-2]
92. 92 Kaufman MS, Radhakrishnan N, Roy R, Gecelter G, Tsang J, Thomas A, Nissel-Horowitz S, Mehrotra B. Influence of pal¬liative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institu¬tional study. Colorectal Dis 2008; 10: 498-502 [PMID: 17949445 DOI: 10.1111/j.1463-1318.2007.01384.x]
93. 93 Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Es¬calante E. Outcomes in the management of obstructive unre- sectable stage IV colorectal cancer. Eur J Surg Oncol 2010; 36: 1187-1194 [PMID: 20864304 DOI: 10.1016/j.ejso.2010.09.005]
94. 94 Seo GJ, Park JW, Yoo SB, Kim SY, Choi HS, Chang HJ, Shin A, Jeong SY, Kim DY, Oh JH. Intestinal complications after pal¬liative treatment for asymptomatic patients with unresect- able stage IV colorectal cancer. J Surg Oncol 2010; 102: 94-99 [PMID: 20578086 DOI: 10.1002/jso.21577]